BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31010758)

  • 1. [Therapeutic options for oligoprogressive non-small cell lung cancer].
    Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
    Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SBRT for oligoprogressive oncogene addicted NSCLC.
    Basler L; Kroeze SG; Guckenberger M
    Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Juan O; Popat S
    Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
    Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
    J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art.
    Franceschini D; De Rose F; Cozzi S; Franzese C; Rossi S; Finocchiaro G; Toschi L; Santoro A; Scorsetti M
    Crit Rev Oncol Hematol; 2020 Apr; 148():102894. PubMed ID: 32062314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
    Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Jairam V; Park HS; Decker RH
    Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
    Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
    Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
    Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
    Bansal P; Rusthoven C; Boumber Y; Gan GN
    Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
    Campo M; Al-Halabi H; Khandekar M; Shaw AT; Sequist LV; Willers H
    Oncologist; 2016 Aug; 21(8):964-73. PubMed ID: 27354669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
    Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
    Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group.
    Borghetti P; Bonù ML; Giubbolini R; Levra NG; Mazzola R; Perna M; Visani L; Meacci F; Taraborrelli M; Triggiani L; Franceschini D; Greco C; Bruni A; Magrini SM; Scotti V
    Radiol Med; 2019 Jul; 124(7):662-670. PubMed ID: 30771218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.
    Tam A; Eustace N; Kassardjian A; West H; Williams TM; Amini A
    Surg Oncol Clin N Am; 2023 Jul; 32(3):497-514. PubMed ID: 37182989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience.
    Borghetti P; Bonù ML; Roca E; Pedretti S; Salah E; Baiguini A; Greco D; Triggiani L; Maddalo M; Levra NG; Alongi F; Magrini SM; Buglione M
    In Vivo; 2018; 32(1):159-164. PubMed ID: 29275314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local control strategies for management of NSCLC with oligoprogressive disease.
    Mavrikios A; Remon J; Quevrin C; Mercier O; Tselikas L; Botticella A; Nicolas E; Deutsch E; Besse B; Planchard D; Barlesi F; Le Péchoux C; Levy A
    Cancer Treat Rev; 2023 Nov; 120():102621. PubMed ID: 37690180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Significance of Surgery for Oligometastatic and Oligoprogressive Non-small Cell Lung Cancer].
    Schmid S; Passlick B
    Zentralbl Chir; 2017 Sep; 142(S 01):S38-S43. PubMed ID: 28958109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer.
    Giraud N; Abdiche S; Trouette R
    Cancer Radiother; 2019 Jul; 23(4):346-354. PubMed ID: 31130373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.